Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-BATs in Advanced Pancreatic Cancer
NCT04137536Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2019
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EGFR BATs in pancreatic cancer (PC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Toxicity at 1 year. Started Oct 2019; status: active, not recruiting.
02
Drugs
EGFR BATs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04137536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04137536.